Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2– Metastatic Breast Cancer 2025
Treatment Pathway for HR+ Metastatic Breast Cancer
ENHERTU LOW-Ultralow Clinical Input on CDA Draft Recommendation
ENHERTU Clinician Group Input CDA and INESSS
TRUQAP Clinician Feedback CDA Draft
TRUQAP Clinician Group Input CADTH
TRUQAP Clinician Group Input INESSS
ITOVEBI Clinican Group Input CDA
ITOVEBI Clinician Group Input INESSS
VERZENIO Clinician Feedback 2L MBC CDA Draft Recommendation
VERZENIO Clinician Group Input 2L MBC CDA
VERZENIO Clinician Input 1L MBC CDA
VERZENIO Clinician Feedback 1L MBC CDA Draft Receommendation
